0 4 CD28 cd28 NN 5 18 costimulation costimulation NN 19 27 augments augment VBZ 28 32 IL-2 il-2 NN 33 42 secretion secretion NN 43 45 of of IN 46 55 activated activate VBN 56 62 lamina lamina NN 63 70 propria propria NN 71 72 T t NN 73 78 cells cell NNS 79 81 by by IN 82 92 increasing increase VBG 93 97 mRNA mrna NN 98 107 stability stability NN 108 115 without without IN 116 125 enhancing enhance VBG 126 130 IL-2 il-2 NN 131 135 gene gene NN 136 151 transactivation transactivation NN 151 152 . . . 154 157 The the DT 158 166 pathways pathway NNS 167 174 leading lead VBG 175 177 to to TO 178 188 activation activation NN 189 191 in in IN 192 198 lamina lamina NN 199 206 propria propria NN 207 208 ( ( ( 208 210 LP LP NNP 210 211 ) ) ) 212 213 T t NN 214 219 cells cell NNS 220 223 are be VBP 224 233 different different JJ 234 238 from from IN 239 249 peripheral peripheral JJ 250 251 T t NN 252 257 cells cell NNS 257 258 . . . 259 261 LP LP NNP 262 263 T t NN 264 269 cells cell NNS 270 277 exhibit exhibit VBP 278 286 enhanced enhance VBN 287 291 IL-2 il-2 NN 292 301 secretion secretion NN 302 306 when when WRB 307 316 activated activate VBN 317 324 through through IN 325 328 the the DT 329 332 CD2 cd2 NN 333 340 pathway pathway NN 340 341 . . . 342 352 Coligation Coligation NNP 353 355 of of IN 356 360 CD28 cd28 NN 361 366 leads lead VBZ 367 369 to to TO 370 381 synergistic synergistic JJ 382 393 enhancement enhancement NN 394 396 of of IN 397 401 IL-2 il-2 NN 402 411 secretion secretion NN 411 412 . . . 413 421 Previous previous JJ 422 429 studies study NNS 430 434 have have VBP 435 448 characterized characterize VBN 449 452 the the DT 453 457 CD28 cd28 NN 458 470 augmentation augmentation NN 471 473 of of IN 474 486 TCR-mediated tcr-mediated JJ 487 496 signaling signaling NN 497 499 in in IN 500 510 peripheral peripheral JJ 511 516 blood blood NN 517 518 T t NN 519 524 cells cell NNS 525 532 through through IN 533 548 transcriptional transcriptional JJ 549 559 activation activation NN 560 562 of of IN 563 565 an an DT 566 570 IL-2 il-2 NN 571 579 promoter promoter NN 580 584 CD28 cd28 NN 585 593 response response NN 594 601 element element NN 602 603 ( ( ( 603 609 CD28RE CD28RE NNP 609 610 ) ) ) 610 611 , , , 612 617 along along IN 618 622 with with IN 623 631 enhanced enhance VBN 632 636 mRNA mrna NN 637 646 stability stability NN 646 647 . . . 648 652 This this DT 653 658 study study NN 659 672 characterized characterize VBD 673 682 molecular molecular JJ 683 689 events event NNS 690 698 involved involve VBN 699 701 in in IN 702 706 CD28 cd28 NN 707 720 costimulation costimulation NN 721 723 of of IN 724 728 IL-2 il-2 NN 729 739 production production NN 740 742 in in IN 743 745 LP LP NNP 746 757 mononuclear mononuclear JJ 758 763 cells cell NNS 764 765 ( ( ( 765 769 LPMC LPMC NNP 769 770 ) ) ) 770 771 . . . 772 776 LPMC LPMC NNP 777 786 exhibited exhibit VBD 787 796 increased increase VBN 797 801 IL-2 il-2 NN 802 812 production production NN 813 815 in in IN 816 824 response response NN 825 827 to to TO 828 832 CD28 cd28 NN 833 846 costimulation costimulation NN 846 847 , , , 848 856 compared compare VBN 857 861 with with IN 862 867 cells cell NNS 868 877 activated activate VBN 878 885 through through IN 886 889 CD2 cd2 NN 890 895 alone alone RB 895 896 . . . 897 901 IL-2 il-2 NN 902 911 secretion secretion NN 912 915 was be VBD 916 926 paralleled parallel VBN 927 929 by by IN 930 939 increased increase VBN 940 950 expression expression NN 951 953 of of IN 954 958 IL-2 IL-2 NNP 959 963 mRNA mRNA NNP 963 964 , , , 965 974 resulting result VBG 975 979 from from IN 980 988 enhanced enhance VBN 989 993 IL-2 il-2 NN 994 998 mRNA mrna NN 999 1008 stability stability NN 1008 1009 . . . 1010 1012 In in IN 1013 1021 contrast contrast NN 1022 1024 to to TO 1025 1040 transcriptional transcriptional JJ 1041 1051 activation activation NN 1052 1054 in in IN 1055 1059 PBMC PBMC NNP 1059 1060 , , , 1061 1065 EMSA EMSA NNP 1066 1074 revealed reveal VBD 1075 1079 that that IN 1080 1084 CD28 cd28 NN 1085 1095 coligation coligation NN 1096 1098 of of IN 1099 1112 CD2-activated cd2-activated JJ 1113 1117 LPMC LPMC NNP 1118 1122 does do VBZ 1123 1126 not not RB 1127 1133 result result VB 1134 1136 in in IN 1137 1146 increased increase VBN 1147 1154 binding binding NN 1155 1157 of of IN 1158 1171 trans-factors trans-factor NNS 1172 1174 to to TO 1175 1178 the the DT 1179 1185 CD28RE cd28re NN 1185 1186 , , , 1187 1190 nor nor CC 1191 1194 did do VBD 1195 1202 Western western JJ 1203 1208 blots blot NNS 1209 1215 detect detect VBP 1216 1223 changes change NNS 1224 1226 in in IN 1227 1240 I-kappaBalpha I-kappaBalpha NNP 1241 1243 or or CC 1244 1256 I-kappaBbeta I-kappaBbeta NNP 1257 1263 levels level NNS 1264 1273 following follow VBG 1274 1278 CD28 cd28 NN 1279 1289 coligation coligation NN 1289 1290 . . . 1291 1302 Furthermore furthermore RB 1302 1303 , , , 1304 1308 CD28 cd28 NN 1309 1319 coligation coligation NN 1320 1325 fails fail VBZ 1326 1328 to to TO 1329 1336 enhance enhance VB 1337 1341 IL-2 il-2 NN 1342 1359 promoter-reporter promoter-reporter NN 1360 1362 or or CC 1363 1368 RE/AP RE/AP NNP 1369 1378 construct construct NN 1379 1389 expression expression NN 1390 1392 in in IN 1393 1406 CD2-activated cd2-activated JJ 1407 1411 LPMC LPMC NNP 1411 1412 . . . 1413 1416 The the DT 1417 1424 results result NNS 1425 1433 reported report VBN 1434 1440 herein herein RB 1441 1449 indicate indicate VBP 1450 1454 that that IN 1455 1458 the the DT 1459 1468 molecular molecular JJ 1469 1479 mechanisms mechanism NNS 1480 1488 involved involve VBN 1489 1491 in in IN 1492 1496 CD28 cd28 NN 1497 1508 cosignaling cosignaling NN 1509 1512 and and CC 1513 1523 regulation regulation NN 1524 1526 of of IN 1527 1531 IL-2 il-2 NN 1532 1541 secretion secretion NN 1542 1544 in in IN 1545 1547 LP LP NNP 1548 1549 T t NN 1550 1555 cells cell NNS 1556 1559 are be VBP 1560 1566 unique unique JJ 1567 1569 to to TO 1570 1574 that that DT 1575 1586 compartment compartment NN 1587 1590 and and CC 1591 1597 differ differ VBP 1598 1602 from from IN 1603 1608 those those DT 1609 1613 seen see VBN 1614 1616 in in IN 1617 1627 peripheral peripheral JJ 1628 1633 blood blood NN 1634 1635 T t NN 1636 1641 cells cell NNS 1641 1642 . . . 1643 1648 These these DT 1649 1661 observations observation NNS 1662 1669 suggest suggest VBP 1670 1671 a a DT 1672 1682 biological biological JJ 1683 1695 significance significance NN 1696 1699 for for IN 1700 1709 different different JJ 1710 1720 mechanisms mechanism NNS 1721 1723 of of IN 1724 1728 IL-2 il-2 NN 1729 1739 activation activation NN 1740 1742 in in IN 1743 1753 initiation initiation NN 1754 1757 and and CC 1758 1769 maintenance maintenance NN 1770 1772 of of IN 1773 1776 the the DT 1777 1785 cytokine cytokine NN 1786 1796 repertoire repertoire NN 1797 1802 found find VBN 1803 1805 in in IN 1806 1809 the the DT 1810 1816 mucosa mucosa NN 1816 1817 . . .